Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.